论文部分内容阅读
目的探讨临床上采用莫西沙星联合依替米星治疗耐多药肺结核患者的近期疗效。方法以95例2012年1月1日-2014年9月1日之间在该院接受治疗的耐多药肺结核患者为研究对象,采用回顾性方法分析,依据治疗手段的不同将其分为对照组(45例)和观察组(50例),前者采用的是常规抗结核治疗联合阿米卡星与左氧氟沙星治疗;后者采用的是常规抗结核治疗联合依替米星与莫西沙星治疗,观察并对比两组患者的用药不良反应发生率、近期治疗有效率与治疗四个月后每个月的痰菌转阴率。结果观察组和对照组在以上观察指标上差异显著,且具有统计学意义(P<0.05)。结论针对耐多药肺结核患者采用莫西沙星联合依替米星治疗,在近期成效上显著,不良反应率小,痰菌转阴率高,值得推广应用。
Objective To investigate the clinical efficacy of moxifloxacin combined with etimicin in the treatment of multidrug-resistant pulmonary tuberculosis patients. Methods 95 cases of MDR-TB patients treated in this hospital from January 1, 2012 to September 1, 2014 were enrolled in this study. The patients were divided into control group (45 cases) and observation group (50 cases). The former used routine antituberculous therapy combined with amikacin and levofloxacin. The latter used conventional antituberculous therapy combined with etimicin and moxifloxacin treatment, Observed and compared the incidence of adverse drug reactions in two groups of patients, the recent treatment efficiency and monthly sputum bacterial conversion rate after four months of treatment. Results The observation group and the control group in the above indicators were significantly different, and with statistical significance (P <0.05). Conclusion Moxifloxacin combined with etimicin treatment for patients with multidrug-resistant pulmonary tuberculosis has achieved significant results in the near future, with a small adverse reaction rate and high negative conversion rate of sputum bacterium, which is worth popularizing and applying.